Annexon Valuation
| ANNX Stock | USD 1.90 0.01 0.53% |
Based on Macroaxis valuation methodology, the firm appears to be fairly valued. Annexon shows a prevailing Real Value of $1.89 per share. The current price of the firm is $1.9. Our model approximates the value of Annexon from analyzing the firm fundamentals such as Shares Owned By Insiders of 0.58 %, return on equity of -0.51, and Current Valuation of (76.78 M) as well as examining its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that Annexon's price fluctuation is dangerous at this time. Calculation of the real value of Annexon is based on 3 months time horizon. Increasing Annexon's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Annexon is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Annexon Stock. However, Annexon's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.9 | Real 1.89 | Hype 1.9 | Naive 2.47 |
The intrinsic value of Annexon's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Annexon's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Annexon helps investors to forecast how Annexon stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Annexon more accurately as focusing exclusively on Annexon's fundamentals will not take into account other important factors: Annexon Total Value Analysis
Annexon is presently estimated to have valuation of (76.78 M) with market capitalization of 209.55 M, debt of 28.97 M, and cash on hands of 177.59 M. The negative valuation of Annexon may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Annexon fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(76.78 M) | 209.55 M | 28.97 M | 177.59 M |
Annexon Asset Utilization
One of the ways to look at asset utilization of Annexon is to check how much profit was generated for every dollar of assets it reports. Annexon shows a negative utilization of assets of -0.3 percent, losing $0.002973 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Annexon shows how discouraging it operates for each dollar spent on its assets.Annexon Ownership Allocation
The majority of Annexon outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Annexon to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Annexon. Please pay attention to any change in the institutional holdings of Annexon as this could imply that something significant has changed or is about to change at the company.Annexon Profitability Analysis
Net Loss for the year was (138.2 M) with profit before overhead, payroll, taxes, and interest of 0.About Annexon Valuation
Our relative valuation model uses a comparative analysis of Annexon. We calculate exposure to Annexon's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Annexon's related companies.Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company was incorporated in 2011 and is headquartered in Brisbane, California. Annexon operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 75 people.
Annexon Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 137.4 M |
Additional Tools for Annexon Stock Analysis
When running Annexon's price analysis, check to measure Annexon's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Annexon is operating at the current time. Most of Annexon's value examination focuses on studying past and present price action to predict the probability of Annexon's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Annexon's price. Additionally, you may evaluate how the addition of Annexon to your portfolios can decrease your overall portfolio volatility.